ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Cipher Pharmaceuticals, Inc. ?
1
High Management Efficiency with a high ROE of 25.10%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 12.64
3
With a growth in Operating Profit of 2.58%, the company declared Very Positive results in Mar 26
- The company has declared positive results for the last 4 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at CAD 41.68 MM
- INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost
- NET PROFIT(HY) Higher at CAD 27.01 MM
4
With ROE of 23.08%, it has a very attractive valuation with a 2.24 Price to Book Value
- The stock is trading at a fair value compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 28.28%, its profits have risen by 230.9% ; the PEG ratio of the company is 0
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Cipher Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Cipher Pharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Cipher Pharmaceuticals, Inc.
28.28%
1.96
42.54%
S&P/TSX 60
29.6%
2.31
12.81%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
20.33%
EBIT Growth (5y)
11.71%
EBIT to Interest (avg)
12.64
Debt to EBITDA (avg)
0.38
Net Debt to Equity (avg)
0.17
Sales to Capital Employed (avg)
0.30
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
37.30%
ROE (avg)
25.10%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
2.24
EV to EBIT
14.86
EV to EBITDA
10.88
EV to Capital Employed
2.30
EV to Sales
5.76
PEG Ratio
0.04
Dividend Yield
NA
ROCE (Latest)
15.45%
ROE (Latest)
23.08%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend21What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CAD 41.68 MM
INTEREST COVERAGE RATIO(Q)
The company hardly has any interest cost
NET PROFIT(HY)
Higher at CAD 27.01 MM
RAW MATERIAL COST(Y)
Fallen by -11.69% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 4.61 times
OPERATING PROFIT(Q)
Highest at CAD 10.15 MM
OPERATING PROFIT MARGIN(Q)
Highest at 59.19 %
-1What is not working for the Company
CASH AND EQV(HY)
Lowest at CAD 19.22 MM
Here's what is working for Cipher Pharmaceuticals, Inc.
Net Profit
At CAD 27.01 MM has Grown at 220.02%
Year on Year (YoY)MOJO Watch
Net Profit trend is very positive
Net Profit (CAD MM)
Operating Cash Flow
Highest at CAD 41.68 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CAD MM)
Net Profit
Higher at CAD 27.01 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (CAD MM)
Operating Profit
Highest at CAD 10.15 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CAD MM)
Operating Profit Margin
Highest at 59.19 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Debtors Turnover Ratio
Highest at 4.61 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -11.69% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Cipher Pharmaceuticals, Inc.
Cash and Eqv
Lowest at CAD 19.22 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
